05/27/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/27/2020. This guidance is for individuals and families who have lost a loved one as they work with funeral directors, community and religious leaders, and others to plan and hold funeral services and visitations during the COVID-19 pandemic. (Text)
05/26/2020 12:00 AM EDT
Source: U.S. Government Accountability Office (GAO). Published: 5/26/2020. This two-page document provides information about COVID-19 vaccine development, including the technology involved, opportunities, challenges, and policy context and questions. As of May 15, 2020, there are more than 110 COVID-19 vaccines in development globally; of those, at least three are being developed in the United States with federal funding. (PDF)
05/26/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 5/26/2020. This nine-page document outlines principles for developing more individualized guidance or operating procedures related to travel in European countries, details travel-related risks, and provides considerations for travel-related measures to reduce spread of COVID-19 in the European Union/European Economic Area (EU/EEA). (PDF)
05/26/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 5/26/2020. This 31-page report aims to provide a short-term 30-day forecast of the expected number of COVID-19 cases, deaths, and hospitalized cases (including general hospital ward and intensive care unit) under a set of assumptions. Mathematical modeling of COVID-19 transmission can be used to better analyze the epidemic development in a population over time, produce projections, and inform public health decision-making on interventions. (PDF)
05/23/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/23/2020. This web page provides guidelines for COVID-19 antibody testing, under these topics: Background, Development of Antibodies and Immunity, Current Status of Antibody Testing in the United States, Types of Antibody Testing, Optimizing Testing Outcomes, Limitations, and Recommendations for Use. (Text)
05/22/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/22/2020. This eight-page letter of authorization details the Emergency Use Authorization (EUA) issued in response to concerns relating to insufficient supply and availability of gowns and other apparel for use by healthcare personnel (HCP) as personal protective equipment (PPE) for use in healthcare settings in accordance with Centers for Disease Control and Prevention (CDC) recommendations to protect both HCP and patients from the transfer of SARS-CoV-2, which causes COVID-19, in low or minimal risk level situations to prevent the spread of COVID-19. (PDF)
05/22/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/22/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Hymon™ SARS-CoV-2 Test Kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 22, 2020. The Hymon™ SARS-CoV-2 Test Kit is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/22/2020 12:00 AM EDT
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 5/22/2020. This one-hour, three-minute webinar from TRACIE (Technical Resources, Assistance Center, and Information Exchange) features interagency partners who provide an overview and discuss the information in the Alternate Care Site (ACS) Funding Summary Tip Sheet. Alternate care sites serve various patient types (e.g., COVID-19 or non-COVID-19) and purposes (e.g., non-acute, hospital, or acute care). (Video or Multimedia)
05/21/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/21/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 21, 2020. The DiaPlexQ COVID-19 Detection Kit is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/21/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/21/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the AQ-TOP™ COVID-19 Detection Kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 21, 2020. The AQ-TOP™ COVID-19 Detection Kit is authorized for use on respiratory specimens collected from individuals who are suspected of COVID-19 by their healthcare provider. (PDF)
05/21/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/21/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the P23 Labs TaqPath SARS-CoV-2 Assay, which received an Emergency Use Authorization from the Food and Drug Administration on May 21, 2020. The P23 Labs TaqPath SARS-CoV-2 Assay is authorized for use on respiratory and saliva specimens from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/21/2020 12:00 AM EDT
Source: American Academy of Pediatrics (AAP). Published: 5/21/2020. The American Academy of Pediatrics is collecting and sharing all publicly available data from states on child COVID-19 cases. This 15-page report provides state-level data on confirmed COVID-19 cases for children; detail varies substantially by state and by week. (PDF)
05/21/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 5/21/2020. To support national governments with COVID-19 surveillance and response planning, the World Health Organization has partnered with Resolve to Save Lives/Vital Strategies and other global partners to launch this 30-page technical package. It provides practical guidance to implement rapid mortality surveillance (RMS) and measure excess mortality in the context of the COVID-19 pandemic, with a focus on implementation in low-resource settings. (PDF)
05/21/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/21/2020. This three-page fact sheet informs healthcare personnel of the significant known and potential risks and benefits of the emergency use of decontaminated, compatible N95 respirators during the COVID-19 pandemic. These compatible N95 respirators have been decontaminated using the STERIS STEAM Decon Cycle in AMSCO Medium Steam Sterilizers. (PDF)
05/21/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/21/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BioCore 2019-nCoV Real Time PCR Kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 21, 2020. The BioCore 2019-nCoV Real Time PCR Kit is authorized for use with upper and lower respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/19/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/19/2020. Given the risks that older adults face from both COVID-19 and dementia, CDC is providing this additional guidance to caregivers of adults with Alzheimer’s disease and other types of dementia to reduce the spread of COVID-19 and to help them manage their patients’ physical and mental well-being, as well as their own well-being. (Text)
05/13/2020 12:00 AM EDT
Source: American Red Cross (ARC). Published: 5/13/2020. This web page provides tips on taking care of yourself and coping during the COVID-19 pandemic. It discusses psychological first aid, and when to seek help. (Text)
05/05/2020 12:00 AM EDT
Source: Healthcare Financial Management Association (HFMA). Published: 5/5/2020. This 14-page document provides voluntary guidance for healthcare providers to code, bill, and seek payment for services rendered in temporary, alternate healthcare sites that may be used during the COVID-19 public health emergency (PHE). (PDF)
05/01/2020 12:00 AM EDT
Source: University of Michigan. Published: 5/2020. The Coronavirus Disability Survey (COV-DIS) was developed by the University of Michigan Center for Disability Health and Wellness in order to learn about the experiences of persons with disabilities (PWD) during the novel coronavirus (COVID-19) pandemic. The psychometric properties of the COV-DIS have not yet been established, but will be disseminated publicly in the future. The objective of the COV-DIS is to provide critical data on the experiences of PWDs during the COVID-19 pandemic. The risk of many adverse health and disability outcomes is elevated in PWDs. The COV-DIS specifically measures general and psychological well-being, difficulty performing activities and instrumental activities of daily living, employment and financial challenges, and difficulty accessing transportation and information. The COVID-19 pandemic and legally mandated social distancing measures have the potential to exacerbate challenges in each of these domains for the population at large, but particularly for PWDs. Data that are acquired using the COV-DIS may be helpful for attending to the needs and challenges faced by PWDs during the current pandemic, as well as for planning for responses to future waves of COVID-19 and other high-impact societal stressors. Questions Adapted From: Several items on the COV-DIS were adapted from survey items from the Understanding America Study (UAS), the Osteoporotic Fractures in Men (MrOS) Study, and the Study of Muscle, Mobility, and Aging (SOMMA) with permission from study investigators, as well as from the RAND 36-item Short Form Survey, and the Patient Health Questionnaire-2. Population: Adults only Length: 32 questions Mode of Administration: Telephone Email Administered by: Self Administered/Self Report Lay Interviewer Language(s): English (PDF)
05/01/2020 12:00 AM EDT
Source: University of California, San Diego (UCSD). Published: 5/2020. The COVID-19 Impact Measure was created to be administered to the participants of the NIH-sponsored Adolescent Brain and Cognitive Development (ABCD) longitudinal study of 11,880 diverse community youth enrolled at age 9-10 in 2016-2018 (i.e., birth years 2006-2009) at 21 research sites around the United States. The ABCD sample (63% White, 20% Latinx, 16% Black, 12% more than one race, 2% Asian, <1% American Indian, <1% Pacific Islander; half female) was targeted to match U.S. demographics as defined by the American Community Survey and is being followed until at least age 20. ABCD will send all currently enrolled participants (age range: 11-13) and their parent/guardian the opportunity to complete the ABCD COVID-19 questionnaires. The questionnaires will be administered once a month for four months. Each participant and their parent/guardian will be emailed a unique secure link to the parent and child forms to complete the survey in REDCap. Compensation will be provided upon receipt of the completed form. These measures were developed by a workgroup consisting of ABCD investigators with expertise in adolescent development, mental health, sleep, physical activity, substance use, and disaster response, and the electronic surveys underwent preliminary testing via expert review and pilot testing with adults and children. Note the Parent Measures contain the English and Spanish wording. The Parent Measure appears in two parts to accommodate parents who have more than one child in the ABCD Study (our design intentionally oversampled identical twins): Part 1 consists of questions that pertain to parent and family factors; Part 2 consists of questions pertaining to each child they have in the study. ABCD's COVID-19 research sends the measure multiple times over several months in 2020; to reduce participant burden, some items have skip-out branching logic and other items are given at one or two survey administrations and other items are administered each time (noted in comments in the measure PDFs). Domains included in the measure: * Family Situation: Home composition, economic impact, illness, parent support * Youth's Schooling: quality, quantity, methods, and supervision * Youth's Routine and Sleep * Relationships: friends and family * COVID Attitudes and Adherence (to public health directives) * Mental Health and Stress: depression, anxiety, worry, post-traumatic stress * Substance Use: alcohol, vaping of nicotine and cannabis, other intoxicants * Screen Use: for school, socializing, other reasons * Media Exposure to COVID-19 * Physical Health: activity, food access, COVID-19 symptoms Population: Adults Only Children/Teens Only Length: ~85-90 items (Youth)* ; ~80-90 items (Parent) *Note: both measures have skip-out branching logic and not all questions may be asked to all participants. Time to Complete: 10-15 minutes Mode of Administration: Online (e.g., computer-assisted interview) Administered by: Self Administered Language(s): English, Spanish (Parent) (PDF)
05/01/2020 12:00 AM EDT
Source: University of Florida (UF). Published: 5/2020. The purpose of this study is to remotely survey older adults about their behaviors, social activities, food security, depression, technology use, and mobility patterns prior to and after the COVID-19 outbreak. We will also ask about practicing COVID-19 precautions during outbreak. This survey knowledge will be critical for targeting educational, policy and behavioral interventions designed to regain and/or modify older adults life activities post-COVID-19. Potential participants will either enter or click on the weblink to access the survey. The front page will contain the following information: broad purpose, optional nature of the survey, amount of time the survey takes, HIPAA compliances, risks, privacy, and research staff contact information in case of questions. The survey is approximately 200 questions depending on responses and skip patterns. It takes about 30-45 minutes to complete. The surveys are broken into logical domains and are ordered in the manner to capture the most important information first. Questions under each module listed below represent elements of validated surveys from PROMIS and others in the literature. Some have been modified to capture changes since the COVID-19 outbreak. The bottom of each module contains a “submit” button at which time the data are saved. Population: Adults Only Length: 200 questions Time to complete: 30-45 minutes Mode of administration: Online (e.g., computer-assisted interview) Special considerations for Administration: must be taken online at https://is.gd/surveycovid Administered by: Self Administered Language(s): English (PDF)
05/01/2020 12:00 AM EDT
Source: Tulane University. Published: 5/2020. This is a sub-study of an NIH funded R01. The goal of the main study is to find out if community chlamydia screening of young men will reduce infection rates in women. The sub-study was to examine how sexual behavior changed as a result of the stay at home order in order to better understand how to interpret our testing rates in the main study. Questions Adapted From: The survey questions are our own questions that we have refined over 20 years of research. Population: High Risk/Special/Unique Populations Length: 51 questions Time to Complete: 15 minutes Mode of Administration: Online (e.g., computer-assisted interview) Administered by: Self Administered Language(s): English only (PDF)
05/01/2020 12:00 AM EDT
Source: Columbia University. Published: 5/2020. The COVID-19 Experiences (COVEX) questionnaire was developed by investigators from the Division of Child and Adolescent Psychiatry at Columbia University/New York State Psychiatric Institute for use in our ongoing and new research studies and by affiliated clinical settings to document the experiences of research participants and patients in the time of the COVID-19 pandemic. COVEX can be administered either as an interview or as a self-report measure. It is being translated in other languages. Section 1: COVID-19 Symptoms & Diagnoses Section 2: Vulnerability to COVID and Direct Exposure Section 3: Living Situation Section 4: Employment/School Changes Section 5: Worries, Mental Health Changes Section 6: Problems and Support during COVID-19 outbreak Section 7: Coping Section 8: Pregnancy-Related Questions (optional) Section 9: Media Use Questions Adapted From: The following measures were adapted for the development of this survey: * Harkness, A. (2020). The Pandemic Stress Index. University of Miami. o Section 5 (7a, 7b, 7c, 7j) o Section 6 (2, 3) * Kroenke, K. & Spitzer, R.L. (2002). The PHQ-9: A new depression and diagnostic severity measure. o Section 5 (1a-1i, 4a-4i) * Kroenke K, Spitzer RL, Williams JB, Monaha PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146:317-25. o Section 5 (1j, 1k, 4j, 4k) * [KFF Coronavirus Poll (conducted March 11-15, 2020)], (KFF, [March 17, 2020]), (http://files.kff.org/
05/01/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 5/2020. This webinar series features country experiences with safety risks to patients and healthcare workers during the COVID-19 pandemic. There is still only limited information on what the impact is on patient safety, both for the patients with COVID and also other non-COVID patients, and on the health workers. (Video or Multimedia)
05/01/2020 12:00 AM EDT
Source: University of Michigan. Published: 5/2020. The AURORA-CIS is a newly designed short survey to learn and understand the impact of the coronavirus (COVID-19/SARS-CoV-2) pandemic on the trauma survivors currently enrolled in the AURORA Study. This supplementary survey was created to assess the additional impact of the pandemic on the mental health outcomes of the study participants beyond that which could be associated with the traumatic event that led to their emergency room visit. There are four questions asked weekly and an additional fifth question included every month. All questions appear at the end of the participants' regularly deployed weekly smartphone-based flash survey. The AURORA Study is a 12-month longitudinal study that represents a major national initiative to improve the understanding, prevention, and treatment of post-traumatic neuropsychiatric sequelae. Five thousand participants who present to the emergency department (28 sites) for evaluation after trauma exposure, meet screening and eligibility criteria, and consent to the study will undergo a brief emergency department assessment of trauma-related, psychosocial, neurocognitive, and biological factors. Participants will be discharged with ecological monitoring, and will complete physiologic, biologic, neurocognitive, symptom, and health outcome assessments during one-year follow-up. Subsamples of study participants will undergo in-person deep phenotyping at two weeks and six months, consisting of biologic collection, functional magnetic resonance imaging (fMRI), and psychophysical evaluation. The COVID survey items will be administered to both existing and newly enrolled participants. No pilot testing for the questions was done. Population: Adults only Length: 5 questions Mode of Administration: Online (e.g., computer-assisted interview) Administered by: Self Administered Language(s): English (PDF)
05/01/2020 12:00 AM EDT
Source: Wellcome Trust. Published: 5/2020. In this questionnaire, we ask about self-isolation, social distancing, and what you have been doing during lockdown. By self-isolation, we mean not leaving home for any reason and possibly keeping away from other members of your household (if you or they are showing symptoms). By social distancing, we mean minimizing contact with other people outside the home. By lockdown, we are referring to the announcement made in the United Kingdom by the government on March 23, 2020, to stay at home, except for very limited purposes. Includes questions related to health, behavior change, economic impact, social impact, and environmental changes. Questions Adapted From: Questions developed by existing UK cohorts: ALSPAC, South Asia Biobank, COSMOS/SCAMP/Airwave, National blood donor cohort, SAPRIN, EXCEED, TwinsUK, Born in Bradford, Generation Scotland, ELSA, CLS cohorts. These and other studies have used some or all of the questions within their cohorts. Length: 107 questions Mode of Administration: Online (e.g., computer-assisted interview) Administered by: Self Administered Language(s): English (PDF)
04/30/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 4/30/2020. This web page provides guidance for coping with stress during the COVID-19 pandemic. Topics cover: Outbreaks can be stressful; Everyone reacts differently to stressful situations; Take care of yourself and your community; People at higher risk; Coming out of quarantine; and Responders. (Text)
04/01/2020 12:00 AM EDT
Source: European Union, European Commission. Published: 4/2020. This three-page document is a European roadmap toward lifting COVID-19 containment measures, with four criteria that include next steps. (PDF)
04/01/2020 12:00 AM EDT
Source: Center for the Study of Traumatic Stress [Uniformed Services University of the Health Sciences] (CSTS). Published: 4/2020. This two-page fact sheet provides helpful information for families (or those caring for them) to help cope with their loss after the death of a loved one from COVID-19, when the death is unanticipated and families are separated from their hospitalized loved one due to potential contagion. (PDF)
04/01/2020 12:00 AM EDT
Source: Center for the Study of Traumatic Stress [Uniformed Services University of the Health Sciences] (CSTS). Published: 4/2020. This two-page document provides several strategies to help families cope while their relatives are hospitalized due to COVID-19. These hospitalizations can be extremely challenging not only for patients, but also for families who might experience distress due to uncertainty about a loved one’s recovery, and also due to personal risk of contracting the disease. (PDF)
03/30/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 3/30/2020. This web page discusses how everyone can help stop stigma related to COVID-19 by knowing the facts and sharing them with others in their community, and how communicators and public health officials can help counter stigma during the COVID-19 response. (Text)
03/01/2020 12:00 AM EST
Source: National Child Traumatic Stress Network (NCTSN). Published: 3/2020. This 170-page document provides guidance on responding to disaster, violence, or terrorism events using the Skills for Psychological Recovery intervention. This approach helps to assist children, adolescents, adults, and families in the aftermath of disaster and terrorism. The manual includes in-depth information about each of the six core skills and accompanying handouts for survivors. It is co-published with the National Center for PTSD. (PDF)
No hay comentarios:
Publicar un comentario